SEC Comment Letter 0000000000-24-003342 to ASLAN Pharmaceuticals Ltd (CIK 0001722926)
ASLAN Pharmaceuticals Ltd (CIK 0001722926)
Date: March 28, 2024 · CIK: 0001722926 · Accession: 0000000000-24-003342
AI Filing Summary & Sentiment
File numbers found in text: 333-278217
Letter
United States securities and exchange commission logo March 28, 2024 Kiran Asarpota Chief Operating Officer ASLAN Pharmaceuticals Ltd 3 Temasek Avenue Level 18 Centennial Tower Singapore 039190 Re:ASLAN Pharmaceuticals Ltd Registration Statement on Form F-3 Filed March 25, 2024 File No. 333-278217 Dear Kiran Asarpota: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Carlos Ramirez
Show Raw Text
United States securities and exchange commission logo
March 28, 2024
Kiran Asarpota
Chief Operating Officer
ASLAN Pharmaceuticals Ltd
3 Temasek Avenue
Level 18 Centennial Tower
Singapore 039190
Re:ASLAN Pharmaceuticals Ltd
Registration Statement on Form F-3
Filed March 25, 2024
File No. 333-278217
Dear Kiran Asarpota:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Carlos Ramirez